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Abstract Autophagy is a critical cellular housekeeping
process that is essential for removal of damaged or
unwanted organelles and protein aggregates. Under con-
ditions of starvation, it is also a mechanism to break down
proteins to generate amino acids for synthesis of new and
more urgently needed proteins. In the heart, autophagy
is upregulated by starvation, reactive oxygen species,
hypoxia, exercise, and ischemic preconditioning, the latter
a well-known potent cardioprotective phenomenon. The
observation that upregulation of autophagy confers pro-
tection against ischemia/reperfusion injury and inhibition
of autophagy is associated with a loss of cardioprotection
conferred by pharmacological conditioning suggests that
the pathway plays a key role in enhancing the heart’s tol-
erance to ischemia. While many of the antecedent signaling
pathways of preconditioning are well-defined, the mecha-
nisms by which preconditioning and autophagy converge to
protect the heart are unknown. In this review we discuss
mechanisms that potentially underlie the linkage between
cardioprotection and autophagy in the heart.
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Signaling to regulate autophagy
Macroautophagy (autophagy) is a downstream effector
pathway that is essential for clearing cellular damage and
the long-term homeostasis of cells and tissues [12, 13, 35,
58, 71, 89]. Information obtained using multiple model
systems shows that the autophagy/lysosomal pathway
responds to a variety of environmental and internal stimuli
to mediate the bulk clearance of extraneous or damaged
cellular components. The observation that starvation or
caloric restriction rapidly induces autophagy in many tis-
sues and is in part regulated by the insulin pathway (via
TOR kinase) suggests that suppression of autophagy, due
to excessive caloric intake, may significantly contribute to
deleterious health effects associated with obesity, meta-
bolic syndrome, type-II diabetes or cellular processes
linked to aging [18, 22, 26, 94].
The link between metabolic syndrome and pathological
metabolic profiles has brought into focus this condition as a
risk factor for poor cardiac outcome, both in terms of car-
diovascular disease and progressive heart failure. Our recent
work has demonstrated that murine myocytes mount a robust
autophagic response, which is protective during periods of
acute stress such as simulated ischemia and reperfusion
[33, 35, 40]. Fasting is well known to induce autophagy in
cardiac myocytes [40, 59, 68]. There is growing evidence
that aerobic exercise may mediate its cardioprotective
effects by upregulating autophagy [17, 29, 45, 54, 56, 77, 85].
These findings imply that the cardioprotective effects
afforded by a robust autophagic response during an acute
episode of ischemia may be suppressed in people that have
metabolic syndrome, Type II diabetes, or sedentary life-
styles. Interestingly, amino acids (particularly Leu, Tyr, and
Gln) and insulin suppress autophagy through independent
pathways [43] and Elazar’s group recently showed
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autophagy is potently induced by removal of a single amino
acid if it is arginine, lysine, leucine, or methionine [87].
Further work will be required to establish whether high-
protein diets or dietary amino acid supplements can suppress
autophagy in mammalian cardiomyocytes.
In recent studies of autophagy gene expression patterns
in Drosophila, message levels of the Atg2, Atg8a, Atg18
and bchs genes decline with age while substrates normally
cleared by the pathway, like insoluble ubiquitinated pro-
teins, increase dramatically [89]. Changes in ubiquitinated
protein profiles are similar to those detected when key
autophagy genes from both Drosophila and mouse models
are genetically altered, a finding which underscores the
highly conserved nature of the pathway [27, 36, 50].
Recently an additional link between autophagy and meta-
bolic disorders has arisen from work done on the
autophagic protein, Sequestosome-1 [p62 or Ref(2)P in
Drosophila] [39, 69]. The p62 protein is required to specify
and facilitate the clearance of protein inclusions or cellular
aggregates by autophagy. Interestingly, genetic deletion of
murine p62 results in viable adult mice that develop insulin
resistance and obesity as early as 4 months of age [83].
Machinery of autophagy
Autophagy is a remarkably flexible and dynamic cellular
process that involves the de novo synthesis of cytoplasmic
organelles, which are transported to and fuse with lyso-
somes, where their contents are degraded and recycled.
Figure 1 is a schematic representation of the pathway and
illustrates the sequestration of individual cargos located
in the cytoplasm (i.e. organelles, ubiquitinated protein
inclusions) by a growing isolation membrane or phago-
phore. Early molecular events required for vesicle
formation involve the coordinated response of two ubiq-
uitin-like pathways that involve the conjugation of the
Atg12 and Atg8 proteins and are illustrated in Fig. 2. In the
case of the Atg12 protein, it first undergoes conjugation to
the E1-like ligase Atg7 via its C-terminal glycine. Atg12 is
then ‘‘transferred’’ to Atg10 (E2-like protein) followed by a
final ligation with the Atg5 protein. The Atg12–Atg5
conjugate then goes on to form a tight non-covalent asso-
ciation with Atg16 protein, producing a trimeric complex.
Upon formation of a high molecular weight Atg12/Atg5/
Atg16 multimer (350KD), the complex localizes to the
outer surface of a growing cup-shaped phagophore.
At the same time, a second ubiquitin-like molecule,
Atg8, also known as microtubule-associated light chain 3
(LC3), undergoes C-terminal cleavage (via the Atg4 cys-
teine protease) to expose a reactive glycine. Atg8/LC3 then
undergoes conjugation to Atg7 (E1-like) before being
passed on to the Atg3 protein (E2-like enzyme via a thio-
ester bond). From there, Atg8/LC3 forms a C-terminal
covalent linkage to phosphatidylethanolamine lipid (PE)
through an amide bond (Atg8-PE) and becomes an integral
component of the membrane located on both external and
lumenal sides of the growing phagophore. Once auto-
phagosome formation is complete (closure of the
phagophore into a mature vesicle), most of the external
‘‘coat’’ protein complexes (Atg12/5/16) dissociate and the
mature autophagosome is ready for transport to and fusion
with the lysosome. The Atg8-PE molecules located within
the vesicle lumen are retained along with the sequestered
cargo and will eventually be degraded by low lysosomal
pH and hydrolases, but until its degradation, Atg8/LC3 is a
Fig. 1 Key cellular components required for autophagosome forma-
tion, transport, and fusion. Adaptor proteins recognize targets for
engulfment (Bchs/Alfy recognizes ubiquitin-rich protein aggregates)
in conjunction with p62/Sequestosome1/Ref(2)P. The forming auto-
phagosome (phagophore) is initially decorated with Atg5:Atg12
conjugates complexed with Atg16, followed by Atg8/LC3, which is
covalently linked to phosphatidylethanolamine (PE). Once the
autophagosome seals around its target, externally exposed Atg
proteins dissociate (internal LC3 is retained) and the vesicle is
transported along microtubules to fuse with a lysosome. The vacuolar
proton ATPase acidifies the autophagosome before fusion with a
lysosome (also acidified). Upon fusion, the contents of the autopha-
golysosome are degraded, including LC3
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reliable molecular marker of autophagosomes and auto-
phagolysosomes (also called autolysosomes). Other critical
elements of autophagy that are the subject of intense
research include mechanisms of substrate specification,
lipid recruitment to the growing phagophore (i.e. Atg9,
Atg11), microtubule transport and vesicle fusion events.
Other components of autophagy/lysosomal pathway are
known to have a role in the heart’s response to stress. Both
Class I and Class III phosphatidylinositol 3-kinases (PI3K)
regulate autophagy by suppressing or activating the pathway
through the production of phosphorylated phosphatidyl-
inositol derivatives. The class III PI3K is composed of a
trimeric protein complex consisting of Beclin1 (Atg6),
Vps15 and hVps34 (Vps14 is also required in yeast) and
produces the second messenger molecule phosphatidylino-
sitol 3-phosphate. In contrast, the Class I PI3K is located
mainly at the plasma membrane and inhibits autophagy by
activating the Akt pathway, with signaling to mTOR. Con-
fusingly, Akt signaling is cardioprotective [88] despite its
predicted suppression of autophagy. Enhanced expression of
Beclin1 in cultured cardiomyocytes (HL-1 cells) was shown
to increase autophagosome formation and pathway flux,
following simulated ischemia reperfusion (sI/R) [7, 35].
Conversely, knockdown of Beclin1 (via RNAi) perturbs the
formation of autophagosomes in cardiomyocyte as well as
the cell’s ability to respond to starvation and sI/R. Similar to
the protection afforded by rapamycin, cells transiently
transfected with a Beclin1 expression construct show
significant protection against sI/R-induced GFP-Bax trans-
location [35].
Clearance of autophagosomes depends upon their deg-
radation after fusion with the lysosome. The fusion event
depends upon acidification, which is accomplished by the
vacuolar proton ATPase (VPATPase) [46]. Like autophagy
genes Atg5 and Atg7, lysosomal function is critical for the
long-term function and maintenance of the heart. Lyso-
somal cysteine peptidase cathepsin L (CTSL) is the
primary protease involved with degradation of intracellular
protein. Targeted knockout of the mouse CTSL gene leads
to dilated cardiomyopathy phenotypes that are similar
to those seen in humans [76]. At the subcellular level
CTSL-/- myocytes show an increased number of lyso-
somes with abnormal characteristics that suggest vesicle
fusion defects. Autophagic defects are also associated with
mutations to the lysosomal-associated membrane protein 2
(LAMP-2). Mutations in the human LAMP-2 gene are
associated with Danon disease [21]. Patients with this
disorder show glycogen storage defects and abnormal
accumulation of autophagic compartments in the heart and
skeletal muscle which leads to acute cardiomyopathy and
myopathy. Transgenic mice lacking LAMP-2 also show
similar accumulation defects in autophagic vesicles found
in heart, muscle, pancreas and liver cells [25]. Together
these finding further highlight the importance of the auto-
phagic/lysosomal pathway in maintaining cardiac viability.
Pharmacologic and molecular tools to study autophagy
The study of autophagy was accelerated by the cloning of
many of the genes involved in the pathway in yeast [62].
Subsequently it was found that these genes are highly
conserved throughout evolution [63, 64]. A second advance
was the introduction of GFP–LC3. Overexpression of this
Fig. 2 Autophagy requires the
activity of two-ubiquitin-like
pathways. Atg8 and Atg12 both
resemble ubiquitin. Atg4 is a
cysteine protease that removes
the terminal cysteine of Atg8
(LC3) to expose the glycine that
is used for conjugation via Atg7
(E1-like) and Atg3 (E2-like)
enzymes to the acceptor
phosphatidylethanolamine.
Atg12 is conjugated to Lys130
in Atg5 via Atg7 and Atg10
(E2-like). Following
conjugation of Atg12–Atg5, a
heteromeric complex forms
with Atg16 that binds to the
convex face of the phagophore
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fusion protein allowed visualization of autophagosomes in
real time in cells and subsequently followed in tissues of
the GFP–LC3 transgenic mouse [65]. Recently, we gen-
erated transgenic mice expressing mCherry–LC3 driven by
the a-myosin heavy chain promoter, which has allowed
monitoring of autophagy in the heart [40]. Imaging auto-
phagosome abundance with these fluorescent fusion
proteins in cells or transgenic animals has become the
‘‘industry standard’’ for measuring autophagy. A thorough
discussion of the advantages and disadvantages of various
methods to monitor autophagy was published by Klionsky
et al. [49] in 2008 and represents the consensus of over 200
authors.
Autophagosomes can accumulate when fusion with
lysosomes is prevented, leading to a mistaken interpreta-
tion that autophagy is upregulated in all cases where
numerous LC3-labeled puncta are seen; thus it is important
to assess flux in order to have an accurate understanding of
the process. One strategy for measuring flux is to compare
the abundance of autophagosomes at steady state and after
lysosomal degradation is inhibited [7]. In the case of
ischemia/reperfusion, flux is impaired and the accumula-
tion of autophagosomes is not an indication of increased
autophagy [35]. Lysosomal degradation can be blocked
with Bafilomycin A1, an inhibitor of the vacuolar proton
ATPase that drives acidification of the organelle [101].
This is often used in tandem with lysosomal protease
inhibitors such as pepstatin and E64d, but blocking acidi-
fication is generally sufficient, as lysosomal proteases such
as cathepsin D have a pH optimum below 4.0 and are
inactive above pH 5.5 [78]. Activity of cathepsin B, a
predominant lysosomal protease, can be assessed using
(z-RR)2-MagicRed-Cathepsin B substrate (B-Bridge).
Bafilomycin is a natural product derived from a fungus, and
as such, nature has evolved a molecule with high speci-
ficity; however, this reagent is moderately expensive. A
modestly less effective reagent is chloroquine, which is a
weak base that accumulates in lysosomes and neutralizes
the pH, thereby preventing lysosomal degradation of
autophagosomes (and possibly fusion of autophagosomes
with lysosomes), resulting in an accumulation of auto-
phagosomes. An advantage of chloroquine is its low cost,
making it suitable for use in vivo [40]. However, chronic
chloroquine administration is known to induce a myopathy
characterized by accumulation of double-membrane LC3-
positive vacuoles (autophagosomes) [91], supporting the
idea that chloroquine prevents autophagosome-lysosome
fusion.
Many investigators have used processing of LC3 to
assess autophagy [42]. When autophagy is activated, LC3-I
is lipidated, resulting in a form that has faster mobility on
SDS-PAGE (LC3-II). The LC3-II/LC3-I ratio is often used
as an indication of increased autophagy. However, this fails
to take flux into account, as LC3-II will be degraded after
the autophagosome fuses with the lysosome [40]. LC3-I
turns over rapidly—possibly by the ubiquitin-proteasome
system—so levels can rise if the ubiquitin-proteasome
system is not functioning well [16]. However, elevated
levels of LC3-II after inhibition of lysosomal degradation
(e.g., with Bafilomycin A1 or chloroquine) can be taken as
an indication of increased autophagy, if appropriate con-
trols are performed.
Studies with LC3–GFP and LysoTracker RedTM
(Invitrogen), which labels lysosomes, have found limited
co-localization, in part because GFP fluorescence dimin-
ishes in the acidic environment of the lysosome. LC3
associated with the outer face of the autophagosomal
membrane is removed following lysosomal fusion, while
internally exposed LC3 is proteolytically degraded. In
contrast, LC3 fused to red fluorescent protein (RFP) or
mCherry does not quench in acidic pH, and thus persists
for a longer time after lysosomal fusion. A tandem
LC3–GFP–RFP construct has been described that allows
estimation of flux by comparing the ratio of GFP to RFP.
Monodansylcadaverine has been used by some to measure
autophagy [66]. This fluorescent diamine co-localizes
with LC3–mCherry-labeled structures in the heart [40].
Whether the accumulation is related to pH of the vesicle
or its unique lipid architecture has been debated [70], but
we have been able to label autophagosomes from frozen
and thawed heart tissue; while it is possible that the pH
gradient is retained, we consider it more likely that the
dye is incorporated due to the double-membrane lipid
structure and potentially unique lipid composition. Sub-
sequently we have adopted cadaverine probes that are
modified with either Alexa-Fluor 488TM or BODIPY-
Texas RedTM (Invitrogen) and have developed a protocol
to measure autophagy in frozen biopsy tissue, based on
cadaverine binding [75].
An important approach to understanding the functional
significance of autophagy is to perturb the system and
monitor the effects on cells. Two small-molecule reagents
for inhibiting autophagy are available: 3-methyladenine
(3MA), and wortmannin. Both agents inhibit the initiation
phase of autophagy by inhibiting PI3K, but wortmannin
and 3MA inhibit class I PI3K (activator of Akt) as well as
class III PI3K Vps34 (activator of autophagy). Since Akt
functions in critical survival pathways, inadvertently
inhibiting Akt could complicate interpretation of experi-
ments designed to assess the role of autophagy when
wortmannin is employed. The 3MA also suffers from
limitations, as it has effects on intermediary metabolism
[8]. Isoform-selective PI3K inhibitors are in development,
but their use for selective inhibition of autophagy remains
to be evaluated [98]. Bafilomycin and chloroquine can
inhibit the degradation phase of autophagy, but this
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requires some time for feedback inhibition of the process
and so these inhibitors may not be informative. Many
agents are known to stimulate autophagy; best-known is
rapamycin, the cognate inhibitor of mTOR, which func-
tions as the central control for catabolic and anabolic
pathways. Recently, contradictory studies have emerged, in
which agents either increase or decrease autophagy,
including statins and aminoimidazole carboxamide ribo-
nucleotide (AICAR) [1, 86, 97]. This may be related to the
cell type under study, so it will be important to characterize
the effects of the agents in the particular system under
study. For instance, we have found that the adenosine A1
receptor agonist stimulates autophagy in HL-1 cells [100],
while others have reported that it inhibits autophagy in
hepatocytes [86].
For these reasons, there has been a move to genetic
models, notably Beclin1(?/-) mice, Atg5(-/-) mice, and
others. These models are informative, but here again,
caution is necessary, and compensatory upregulation of
other gene products may occur that confound the inter-
pretation. For instance, ERK is substantially upregulated in
Atg5(-/-) embryonic fibroblasts, which could offer pro-
tection against some insults unrelated to autophagy [80].
Moreover, both Beclin1 and Atg5 contain a BH3 domain
[57, 79]. Cleavage of Atg5 by calpain exposes the pro-
apoptotic BH3 domain and triggers apoptosis [102]. We
have developed a cell-permeable inhibitor of autophagy,
Tat-Atg5K130R, which blocks the induction of autophagy
within a few minutes of its introduction, and which
therefore allows a more targeted and selective intervention.
It is important to point out a caveat in the use of LC3–GFP
(or LC3–mCherry) transgenic mice: since LC3 is a rate-
limiting protein in the autophagy pathway, constitutive
overexpression may upregulate basal levels of autophagy,
with resulting effects on cellular and organ physiology. For
this reason it is important to select the lowest-expressing
line and to characterize the relevant parameters of the
system under study. These tools can be used to understand
the role of autophagy in clinically relevant contexts such as
preconditioning.
Role of autophagy in preconditioning
Despite major advances in the treatment of heart disease,
post-ischemic myocardial stunning and infarction remain
a major cause of complications and death in patients
undergoing heart surgery and percutaneous coronary
interventions. For these reasons, considerable efforts are
underway to develop new therapeutic strategies to
increase the heart’s tolerance to ischemia. One approach
has been to elucidate the heart’s endogenous defense
mechanisms and to develop pharmacological agents that
mimic the cardioprotection conferred by ischemic pre-
conditioning and postconditioning [61, 67].
To date, the results using this approach, however, have
been disappointing. This is due, in part, to the fact that
most of these efforts have focused primarily on various
upstream triggers and signaling pathways rather than
defining the precise intracellular mechanisms that are
involved or the end effectors. Recently, it was shown that
agents known to mimic pharmacological conditioning are
also potent inducers of autophagy. This offers new insights
into the endogenous mechanisms that regulate protection in
the human heart and thereby provides a roadmap for the
development of therapeutic agents that target autophagy.
A number of studies have implicated autophagy in car-
dioprotection. In 2005 Yan et al. [99] showed that
autophagy was upregulated in chronically ischemic myo-
cardium. They noted that autophagosomes were seen in
surviving cells, not apoptotic ones, suggesting that
autophagy might play a beneficial role in chronic low-flow
ischemia. Subsequently, Dosenko [19, 20] noted a con-
nection between preconditioning and autophagy. More
recently, Gurusamy et al. [31, 32] reported that cardio-
protection by adaptation to ischemia (preconditioning) was
mediated by BAG-1 and upregulation of autophagy.
Adenosine is well known as a mediator of preconditioning,
yet its connection to autophagy was unknown until recently
[11]. The essential role for autophagy is revealed in the
study by our group [100], in which we showed that 2-
chloro-N(6)-cyclopentyladenosine (CCPA), an adenosine
A1 receptor agonist and potent cardioprotective agent,
markedly induces autophagy within 10 min of treatment in
GFP–LC3 infected HL-1 cells, neonatal, and adult rat
cardiomyocytes. The salutary effect of this agent in the
setting of simulated ischemia/reperfusion on cell survival
was abolished when the cells were treated with a specific
inhibitor of autophagy, the dominant negative protein
Atg5K130R. It is also possible to infer a role for autophagy
from other studies. Rapamycin, a powerful inducer of
autophagy, has been reported to reduce infarct size in a
Langendorff isolated perfused rat heart model [48]. Statins,
which have been shown to be beneficial in the post-MI
setting in patients, regardless of effects on cholesterol
levels, are also powerful inducers of autophagy. Interest-
ingly, Pravastatin, which showed less benefit in the
PROVE IT-TIMI 22 trial, failed to induce autophagy
[1, 55]. Exercise is another intervention that has been
shown to confer cardioprotection [4, 77] as well as to
induce autophagy [56]. Similarly, lipopolysaccharide
elicits preconditioning and autophagy [96, 103]. Precon-
ditioning is considered to mediate its beneficial effects
during the reperfusion phase [37], and that would suggest
that autophagy plays its role in cardioprotection during the
same window. However, if autophagy is important, it begs
Basic Res Cardiol (2009) 104:169–180 173
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the question, ‘‘Why?’’ The next paragraphs address some
possible explanations for the mechanism of cardioprotec-
tion by autophagy.
Elimination of protein aggregates
The process of autophagy in the heart is also responsible
for the clearance of protein aggregates that occur due to
natural progresses of cellular aging [damage from reactive
oxygen species (ROS)], pressure overload or genetic
mutations that increase the risk of endogenous proteins to
misfold and aggregate. Direct analysis of autophagy in
mice and Drosophila has shown that basal levels of the
pathway are required to remove cytoplasmic protein
inclusions or aggregates containing ubiquitin. Conditional
knockout alleles in the mouse Atg5 and Atg7 genes and
multiple loss-of-function mutations in Drosophila show
that endogenous ubiquitinated proteins in the nervous
system are not effectively eliminated and accumulate as a
result of impaired autophagy [41, 50]. For mice and flies,
the increase in protein aggregates is not due to the presence
of mutant aggregate-prone peptides but rather the accu-
mulation of oxidatively modified proteins due to failed
autophagy [36, 89]. Once the misfolded proteins exceed the
capacity of the proteasome for removal, they form insol-
uble aggregates, which can only be eliminated by
macroautophagy. Cardiac-specific deficiency of Atg5 in
adult mice also results in cardiac hypertrophy followed by
ventricular dilatation and contractile defects accompanied
by increased levels of ubiquitinated proteins [51, 68].
Functional loss of Atg5 during embryogenesis does not
affect cardiac development or biogenesis, but in adult mice
subjected to pressure overload, left ventricular dilatation
develops. These results suggest that basal autophagy serves
a protective homeostatic function in the heart, contributing
to the elimination of damaged proteins that could form
aggregates that would further compromise cardiomyocyte
function and viability.
While the relationship between aggregate-prone proteins
and autophagic clearance is an established hypothesis in
neurodegenerative diseases, the pathway’s ability to elim-
inate misfolded or aggregate-prone cardiac proteins is also
receiving attention. As with familial cases of neurodegen-
eration, gain-of-function mutations in sarcomere or
cytoskeletal proteins can increase the tendency of proteins
to misfold. This defect can then go on to produce early
onset cardiomyopathies or heart failure. These mutations,
as well as environmental stresses, can promote cellular
protein misfolding and can affect the function and turnover
of individual proteins. The best examples are associated
with the mutations in the desmin (intermediate filament
protein) and its chaperone aB-cystallin (small heat shock-
like protein) genes, which result in desmin-related
myopathy disorders (DRM) [92]. Defects in either gene
lead to altered protein profiles, a build-up of misfolded
proteins and aggresomes, and cardiac amyloidosis. Recent
studies have shown upregulation of autophagy in cardiac
myocyte is an adaptive response to the disorder and sup-
pressing the pathway accelerates heart failure.
Sequestration of damaged organelles (mitophagy),
and mitochondrial quality control
Mitochondria undergo continuous remodeling and excess
mitochondria are eliminated by autophagy when ATP
production requirements are low. Mitochondrial quality
control is the process of sorting well-functioning mito-
chondrial components from damaged and dysfunctional
elements through fusion and fission. Highly functional
mitochondria, characterized by efficient ATP production,
high membrane potential, and low levels of ROS produc-
tion, few oxidatively modified proteins, and high levels of
OPA-1 can continue to participate in fusion and fission
events, while damaged mitochondria have low membrane
potential, low levels of OPA-1, are excluded from sub-
sequent fusion events, and are removed by autophagy [95].
This culling process is important to maintaining a popu-
lation of highly functional mitochondria. Recent studies
have shown that mitochondria are frequent targets of
engulfment by autophagosomes during prolonged starva-
tion [15, 52], and our studies in the heart support this
observation. During times of increased energy demand,
mitochondrial biogenesis will be stimulated, and this may
be enhanced if a cycle of mitophagy preceded it. Since
autophagy is upregulated by caloric restriction or exercise
[6, 56], one can imagine that increased mitochondrial
culling will result in a population of high-functioning,
robust mitochondria. This may explain the observation that
caloric restriction or exercise results in mitochondria that
show a higher threshold for permeability transition pore
opening [45], and may also be reflected in an altered pro-
tein composition of the mitochondrial population [28].
Mitochondria are targets of autophagy during cellular
stress including ischemia/reperfusion or oxidative stress
[24]. Since mitochondria can release cytochrome c and
other pro-apoptotic factors and can generate substantial
amounts of ROS after I/R, it is conceivable that autophagy
may protect the cell by sequestering and degrading the
mitochondria that are most likely to trigger apoptosis
(through cytochrome c release) and necrosis [through cat-
astrophic mitochondrial permeability transition (MPT)].
Removal of ROS-producing mitochondria through
autophagy will also decrease the overall oxidative stress
experienced by a cell, which may explain in part why
caloric restriction is associated with less oxidative damage
[77]. Conceivably, any stimulus that results in enhanced
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mitochondrial quality control through autophagy will have
benefits with respect to organ function and aging.
Proteomic analysis of mitochondria from preconditioned
hearts reveals changes in post-translational modifications
and protein composition [2]. It is unknown whether some of
this can be attributed to removal of a subset of effete mito-
chondria through autophagy, but is certainly a possibility
given the critical role of autophagy in preconditioning [31,
32, 74, 100]. What is clear from these studies is that
autophagy plays a critical role in cardioprotection. Studies
from the Atg5(-/-) animals have already shown an
essential role for housekeeping autophagy in maintaining
cardiac function. Thus, autophagy appears to play an
important role in the heart. Since cardiomyocytes are long-
lived cells, it would be important to be able to maintain
optimal function of each cell, and the evidence now suggests
that autophagy is essential to that process. Oxidative stress
leads to damaged mitochondria, which are removed through
autophagy in what may a Bnip3-dependent process [38, 53].
Subsequently, mitochondrial biogenesis is stimulated, and
may be linked to autophagy [81, 82]. Studies of heart pro-
teins over the circadian cycle has revealed substantial
changes in the abundance of many mitochondrial proteins
[23]; removal of mitochondria by autophagy during periods
of low activity would lower the oxidative stress experienced
by the cell, and would facilitate mitochondrial biogenesis,
resulting in replacement of deteriorated components. Mito-
chondria are important targets of autophagy, which serves a
beneficial role in mitochondrial quality control. High-qual-
ity mitochondria exhibit efficient ATP production and
resistance to stimuli that would trigger the MPT. Conditions
that suppress mitophagy—such as caloric excess—would be
expected to result in the accumulation of damaged, ineffi-
cient mitochondria with a low threshold for MPT.
There is growing evidence to support the notion that
damaged mitochondria are selectively removed by
autophagy. Lemasters and collaborators [24] showed that
photodamaged mitochondria were selectively engulfed by
autophagosomes, and Shirihai’s group showed that mito-
chondria with lower membrane potential were removed by
autophagy while those with high membrane potential
underwent successive cycles of fusion and fission [95].
Since mitochondrial protein import depends upon high
membrane potential, only this subset of mitochondria can
replace damaged proteins. Inhibition of autophagy prevents
removal of the low membrane potential mitochondria, with
the result that oxidatively damaged proteins and poorly
functioning mitochondria accumulate within the cell,
accompanied by inefficient ATP production. This suggests
that autophagy is important to maintain high-functioning
mitochondria. For this reason, suppressing autophagy will
have significant adverse consequences for mitochondrial
homeostasis, and may explain, in part, the severe
cardiomyopathy seen in several mouse models in which
autophagy is impaired (Atg5-null, Atg7-null, LAMP-null,
and Danon disease) (see reviews [33, 34]). Furthermore,
we suggest that clinical conditions in which autophagy is
suppressed will also lead to the accumulation of poor
quality mitochondria; such conditions include hyperinsu-
linemia and caloric excess. Like so much of biology, too
much of a good thing can be bad. There are conditions
when excessive autophagy (and mitophagy) may lead to
depletion of mitochondria beyond a critical level required
to support the needs of the cell. This may explain why
partial inactivation of autophagy [Beclin1(?/-) mice] do
better than their wild type counterparts when subjected to
severe aortic banding [84].
Protein breakdown to yield metabolic substrates
for ATP production
There is profound nutrient limitation during ischemia.
Autophagy represents a compensatory response to nutrient
limitation and is regulated by AMP-activated kinase
(AMPK), hypoxia, and low ATP levels [59, 60, 73].
However, our studies indicate that the formation of auto-
phagosomes is suppressed in HL-1 cells during simulated
ischemia. During reoxygenation or reperfusion, more
autophagosomes are present, but we still find that clearance
of the autophagosomes is impaired [35]. When autophagy
proceeds efficiently, products of protein degradation (short
peptides and amino acids) can be transported out of the
autophagolysosome. The amino acids can be used as sub-
strates for oxidative phosphorylation; however, they can
also be used for non-oxidative ATP production. For
instance, glutamine can serve as an important energy
source independent of mitochondrial respiration [14].
Interestingly, the peptides can be used for antigen presen-
tation on Class II major histocompatibility complex
molecules, revealing another connection between autoph-
agy and immunity. Little work has been done to
characterize the amino acid transporters present in the
autophagolysosome.
Amino acid transport for glutathione biosynthesis
A proteomic study of hepatic autophagosomes identified
numerous enzymes involved in sulfhydryl repair [72]. The
purpose of these enzymes for repair of oxidatively dam-
aged proteins in the lumen of the autophagosome seems
unlikely; rather, we hypothesize that the autophagolysos-
omal membrane serves as a scaffold for repair of
cytoplasmic proteins. Amino acids liberated by proteolytic
degradation of lumenal contents would be transported
across the membrane, providing the driving force for
glutathione biosynthesis. Multiple other enzymes involved
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in sulfhydryl repair might assemble in proximity to the site
of glutathione biosynthesis, as proposed in Fig. 3. It is
appealing to think that autophagy, which is potently
induced by ROS, would be part of a cellular homeostatic
response enabling repair of oxidatively modified sul-
fhydryls. Considerable work lies ahead to determine
whether this speculation will be shown to be true.
Proton pumping to support ion homeostasis
During ischemia, intracellular pH (pHi) drops rapidly to
below 6.6 as lactic acid accumulates and protons are
released from ATP hydrolysis [90]. During early reperfu-
sion, the Na?/H? exchanger operates to eliminate protons,
taking advantage of the driving force of high extracellular
[Na?], resulting in normalization of pHi (sometimes even
an overshoot) and increased intracellular [Na?]. The
intracellular Na? competes with Ca?? for extrusion via the
Na?/Ca?? exchanger, resulting in Ca?? overload, which
in turn activates calpains, leading to proteolytic activation
of pro-apoptotic Bid [9, 10], as well as opening of the
mitochondrial permeability transition pore (MPTP).
Ischemic preconditioning limits intracellular acidification,
thereby preventing Na? and Ca?? overload. In previous
work we showed that this depended upon activity of the
vacuolar proton ATPase (VPATPase), which is the proton
pump responsible for lysosomal acidification [30, 44]. We
now suggest that upregulation of autophagy would neces-
sarily be linked to activation of the VPATPase. In this case,
upregulation of autophagy would be predicted to limit Na?
and Ca?? overload (see diagram). Bafilomycin A1 is a
potent and specific inhibitor of the VPATPase, which is
essential for receptor internalization and endosomal traf-
ficking and could therefore affect adenosine receptor
signaling [93]. One could then argue that the loss of pro-
tection observed by Yitzhaki et al. is due to inhibition of
endosomal trafficking rather than blockade of autophagy.
However, Atg5 is not required for endosome trafficking
[5].
Stimulation of mitochondrial biogenesis
An intriguing link between autophagy and mitochondrial
biogenesis is suggested by studies in which cardiomyocytes
exposed to LPS upregulate autophagy and mitochondrial
biogenesis [38, 103]. Mitochondria are a common target of
autophagy, but a mechanistic link between mitophagy
(autophagy of mitochondria) and mitochondrial biogenesis
is not yet established. Here again, there is room for spec-
ulation that elimination of mitochondria directly signals
mitochondrial biogenesis. To draw a lesson from bacteria
(with which mitochondria share ancestry), bacterial popu-
lations secrete factors that provide information about the
relative density of the population [3]. The concentration of
these factors serves to regulate rates of bacterial replication
and expression of bacterial and host cell genes [47]. By
analogy, mitochondria might also secrete factors that
coordinate their biogenesis. The simplest example of this is
ATP as the ‘secreted factor’ that slows (mitochondrial)
replication by suppressing AMPK; low [ATP] activates
AMPK which in turn activates the key transcription factor
PGC1a to initiate mitochondrial biogenesis. Removal of
mitochondria by autophagy would decrease the concen-
tration of the ‘secreted factor’ (whether ATP or another
molecule), thereby triggering replacement of the missing
mitochondria.
Summary
Autophagy is mechanism to recycle proteins and to remove
unwanted or damaged organelles. It is important for the
removal of oxidized or aggregated proteins. In dividing
cells with rapid turnover, autophagy may not be essential;
however, in long-lived cells such as cardiomyocytes and
neurons, removal of damaged organelles and protein
aggregates is critical to maintaining optimal cellular
function. In particular, autophagy appears to be essential to
mitochondrial quality control. Matching energy production
to cellular energy needs is controlled at multiple levels,
including transcription/translation, post-translational con-
trol, and allosteric regulation; it appears that autophagy
participates in regulation by removing effete mitochondria,
Fig. 3 Putative connection between protein thiol repair and autoph-
agy. Lysosomal hydrolases degrade proteins into peptides (short
lines) and amino acids (dots), which are transported out of the
autophagolysosome, where they may enter the gamma-glutamyl cycle
to generate glutathione, which is utilized by thiol repair enzymes
associated with the autophagolysosome, including glutathione
S-transferase, aryl sulfotransferase and betaine:homocysteine
S-methyltransferase
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thereby permitting biogenesis. Failure of autophagy results
in accumulation of poor-functioning mitochondria and
aggregated proteins. Autophagy may serve additional
functions in the acute setting of stress, including production
of metabolic substrates for energy production and thiol
repair, and may also contribute to pH and ion homeostasis
through proton sequestration. A more detailed under-
standing of the role of autophagy in cardiac health and
disease may offer new therapeutic approaches to the
management of ischemia/reperfusion injury, hypertrophy,
and failure.
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